OF
BCAX

Optimize Financial’s Bicara Therapeutics BCAX Stock Holding History

Optimize Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710K Sell
23,913
-83
-0.3% -$1.85K 0.26% 61
2026
Q1 		$477K Buy
+23,996
New +$413K 0.23% 114

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Optimize Financial's BCAX Position: Q2 2026 in Review

Optimize Financial reduced its Bicara Therapeutics (BCAX) stake by 0.35% in Q2 2026, selling an estimated $1.85K and leaving 23,913 shares worth $710K. The position accounts for 0.26% of the portfolio, ranked #61.

Optimize Financial first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Optimize Financial held 23,913 shares of Bicara Therapeutics worth $710K as of Q2 2026.
  • Optimize Financial sold 83 Bicara Therapeutics shares in Q2 2026, an estimated $1.85K.
  • Bicara Therapeutics made up 0.26% of Optimize Financial's portfolio in Q2 2026, its #61 holding.
  • Optimize Financial first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.